• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    8/17/23 1:31:13 PM ET
    $ADTX
    $ANTX
    $BVS
    $CELL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • PhenomeX (NASDAQ:CELL) shares increased by 136.4% to $0.95 during Thursday's regular session. As of 13:31 EST, PhenomeX's stock is trading at a volume of 19.6 million, which is 2758.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $93.9 million. As per the press release, Q2 earnings came out 3 days ago.
    • Tivic Health Systems (NASDAQ:TIVC) shares increased by 59.98% to $0.11. As of 13:31 EST, this security is trading at a volume of 429.4 million shares, making up 1776.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.7 million. As per the news, the Q2 earnings report came out 3 days ago.
    • Aditxt (NASDAQ:ADTX) shares moved upwards by 36.47% to $0.41. Trading volume for this security as of 13:31 EST is 9.6 million, which is 10968.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.0 million.
    • Modular Medical (NASDAQ:MODD) stock increased by 22.44% to $1.2. Trading volume for this security as of 13:31 EST is 11.3 million, which is 12653.4% of its average full-day volume over the last 100 days. The company's market cap stands at $25.3 million. As per the news, the Q1 earnings report came out 3 days ago.
    • Salarius Pharmaceuticals (NASDAQ:SLRX) stock rose 21.31% to $0.91. Salarius Pharmaceuticals's stock is trading at a volume of 66.2K shares as of 13:31 EST. This is 114.3% of its average full-day volume over the last 100 days. The company's market cap stands at $3.3 million.
    • AN2 Therapeutics (NASDAQ:ANTX) stock rose 16.05% to $10.73. The market value of their outstanding shares is at $235.4 million.

    Losers

    • Fortress Biotech (NASDAQ:FBIOP) shares fell 24.5% to $10.01 during Thursday's regular session. Trading volume for this security as of 13:31 EST is 136.5K, which is 831.5% of its average full-day volume over the last 100 days.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares fell 23.25% to $0.14. As of 13:31 EST, Novo Integrated Sciences's stock is trading at a volume of 44.6 million, which is 291.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.6 million.
    • Bioventus (NASDAQ:BVS) stock decreased by 19.88% to $3.75. As of 13:31 EST, Bioventus's stock is trading at a volume of 563.6K, which is 74.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $235.4 million.
    • Navidea Biopharmaceutical (AMEX:NAVB) stock decreased by 17.09% to $0.08. The current volume of 4.1 million shares is 51.7% of Navidea Biopharmaceutical's average full-day volume over the last 100 days (last updated at 13:31 EST). The market value of their outstanding shares is at $7.6 million.
    • T2 Biosystems (NASDAQ:TTOO) stock fell 16.69% to $0.47. Trading volume for this security as of 13:31 EST is 103.1 million, which is 104.3% of its average full-day volume over the last 100 days. The company's market cap stands at $158.0 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares declined by 15.55% to $0.13. As of 13:31 EST, Alaunos Therapeutics's stock is trading at a volume of 2.6 million, which is 267.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.7 million. As per the press release, Q2 earnings came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $ANTX
    $BVS
    $CELL

    CompanyDatePrice TargetRatingAnalyst
    Bioventus Inc.
    $BVS
    2/9/2026$13.00Outperform
    Barrington Research
    Bioventus Inc.
    $BVS
    7/7/2025$12.00Overweight
    Cantor Fitzgerald
    Bioventus Inc.
    $BVS
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024In-line → Underperform
    Evercore ISI
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    AN2 Therapeutics Inc.
    $ANTX
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    More analyst ratings

    $ADTX
    $ANTX
    $BVS
    $CELL
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/13/26 5:27:44 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SCHEDULE 13G filed by AN2 Therapeutics Inc.

    SCHEDULE 13G - AN2 Therapeutics, Inc. (0001880438) (Subject)

    3/13/26 5:02:05 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Modular Medical Inc. filed SEC Form 8-K: Other Events

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/13/26 4:00:48 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics Announces $40 Million Private Placement Financing

    AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands Capital, Commodore Capital, Vivo Capital and other new and existing institutional investors. In the private placement, AN2 Therapeutics is selling 8,245,611 shares of common stock at a price of $2.85 per share and, in lieu of common stoc

    3/9/26 7:00:00 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on March 9, 2026, the Company's common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company's stockholders at the reconvened special meeting held on February 13, 2026, with the final ratio determined by the Company's board of directors. As a result of the reverse stock split, the CUSIP number for the Company's common stock will now be 007025877. As a r

    3/5/26 8:30:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hanish Arnold C bought $3,740 worth of shares (5,000 units at $0.75) (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/24/25 5:08:13 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec VP Finance, CFO Rosenblum Mark J bought $16,000 worth of shares (20,000 units at $0.80), increasing direct ownership by 11,299% to 20,177 units (SEC Form 4)

    4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

    11/20/25 4:42:09 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcmurry-Heath Michelle sold $105,439 worth of shares (12,000 units at $8.79), decreasing direct ownership by 21% to 44,997 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    3/13/26 5:26:41 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Principal Accounting Officer Williams Sarah Joanne sold $347 worth of shares (327 units at $1.06), decreasing direct ownership by 0.49% to 66,848 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    3/5/26 6:55:23 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Eizen Joshua M was granted 50,000 shares, increasing direct ownership by 32% to 207,499 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    2/23/26 4:41:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barrington Research initiated coverage on Bioventus with a new price target

    Barrington Research initiated coverage of Bioventus with a rating of Outperform and set a new price target of $13.00

    2/9/26 8:08:39 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Cantor Fitzgerald initiated coverage on Bioventus with a new price target

    Cantor Fitzgerald initiated coverage of Bioventus with a rating of Overweight and set a new price target of $12.00

    7/7/25 8:17:29 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus upgraded by Analyst with a new price target

    Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

    12/17/24 7:32:13 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Salarius Pharmaceuticals Inc.

    SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

    11/14/24 4:38:31 PM ET
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by AN2 Therapeutics Inc.

    SC 13G/A - AN2 Therapeutics, Inc. (0001880438) (Subject)

    11/14/24 4:29:18 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $ANTX
    $BVS
    $CELL
    Financials

    Live finance-specific insights

    View All

    Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

    Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options. Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC ("Ignite"), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite's functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be captured by standard genomic testing alone. Aditxt

    3/13/26 8:15:00 AM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026

    DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/24/26 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care